doxazosin has been researched along with celecoxib in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Bender, A; Czobor, P; Jelinek, B; Málnási-Csizmadia, A; Peragovics, Á; Simon, Z; Tombor, L; Végner, L | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Abo-Talib, NF; Bebawy, LI; Moustafa, AA | 1 |
| Jhang, JF; Jiang, YH; Kuo, HC | 1 |
1 review(s) available for doxazosin and celecoxib
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 trial(s) available for doxazosin and celecoxib
| Article | Year |
|---|---|
Adding Cyclooxygenase-2 inhibitor to alpha blocker for patients with benign prostate hyperplasia and elevated serum prostate specific antigen could not improve prostate biopsy detection rate but improve lower urinary tract symptoms.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Aged; Biopsy; Celecoxib; Cyclooxygenase 2 Inhibitors; Doxazosin; Drug Therapy, Combination; Humans; Lower Urinary Tract Symptoms; Male; Middle Aged; Prospective Studies; Prostate; Prostate-Specific Antigen; Prostatic Hyperplasia; Pyrazoles; Sulfonamides; Treatment Outcome; Urination | 2013 |
4 other study(ies) available for doxazosin and celecoxib
| Article | Year |
|---|---|
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Experimental confirmation of new drug-target interactions predicted by Drug Profile Matching.
Topics: Algorithms; Angiotensin-Converting Enzyme Inhibitors; Animals; CHO Cells; Cricetulus; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Dopamine D2 Receptor Antagonists; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Humans; Molecular Conformation; Molecular Targeted Therapy; Peptidyl-Dipeptidase A; Receptors, Dopamine D1; Receptors, Dopamine D2; Structure-Activity Relationship; Substrate Specificity | 2013 |
Stability-indicating methods for the determination of doxazosin mezylate and celecoxib.
Topics: Adrenergic alpha-Antagonists; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Densitometry; Doxazosin; Drug Stability; Pyrazoles; Spectrophotometry; Sulfonamides | 2002 |